Depo-Provera MDL update: the July 2026 numbers families should know

A lot has happened in the Depo-Provera litigation in a short window. If
someone in your family used the birth control shot and was later
diagnosed with a meningioma, do not rely on an article from a few months
ago. The court file has been moving.

Here is the current picture. The federal cases are in MDL No. 3140 in
the Northern District of Florida, before Judge M. Casey Rodgers. The
Judicial Panel on Multidistrict Litigation listed 5,830 pending
Depo-Provera actions as of July 1, 2026. That is the public case count
from the JPML's pending MDL report, not an estimate from a law firm ad.

The court has also put something else on the record: plaintiffs' lead
counsel and Pfizer-related defendants have reached a global agreement
framework for eligible MDL plaintiffs. The court's June order says those
eligible plaintiffs will have an opportunity to resolve their claims. It
also says the agreement is not expected to resolve every case.

That sentence is worth slowing down for. A settlement framework is not
the same thing as a blank check. It is not public proof that every
person with a meningioma diagnosis qualifies. It also does not mean a
family should ignore deadlines while waiting for more details.

How the Depo-Provera MDL got here

The JPML created MDL 3140 in February 2025. In the transfer order, the
Panel described the basic allegations this way: people claimed they used
Depo-Provera, or a generic depot medroxyprogesterone acetate product,
and later developed one or more intracranial meningiomas. The Panel said
the cases shared factual questions about causation, warnings, what
defendants knew, and whether safer alternatives should have been
promoted.

That is the reason the cases were centralized. Instead of hundreds or
thousands of federal courts handling the same company witnesses, warning
history, expert reports, and document fights separately, one court
handles coordinated pretrial work.

By March 2026, the Northern District of Florida reported 3,467 member
case filings and 3,790 unique plaintiffs. By July 1, the JPML report
listed 5,830 pending actions. The pace alone does not prove liability,
but it shows why this litigation is being watched closely.

The Daubert hearing did not disappear

One confusing part of the docket is the expert schedule. The March 2026
case management order said general causation expert depositions were
taking place from late February through March, with Rule 702/Daubert
briefing due to finish by May 29.

Then Pretrial Order No. 30A changed the timing. The court postponed
ruling on Pfizer's federal preemption motion. It also moved the Rule 702
evidentiary hearing from June 24-25, 2026 to July 27, 2026 in Pensacola.

Why keep the expert hearing if a settlement framework exists? The court
answered that directly. The agreement, once finalized, will not resolve
all MDL cases. Some claims may fall outside the eligibility criteria.
Some plaintiffs may need the litigation to keep moving. So the court
said it still anticipated proceeding with the Rule 702 hearing and
ruling in the ordinary course.

For families, the takeaway is simple enough: the MDL is not frozen.
Important expert and legal rulings may still matter, especially for
claims that do not fit inside any eventual settlement program.

The FDA warning is now part of the timeline

Depo-Provera CI is medroxyprogesterone acetate given as an injection
every three months. The current FDA-approved label, revised in December
2025, lists a recent major change for "Warnings and Precautions,
Meningioma." The same label says Depo-Provera CI is not recommended as a
long-term birth control method, meaning longer than two years, unless
other birth control options are considered inadequate.

Many claims focus on earlier use, before the U.S. meningioma warning
appeared. That does not automatically make a case strong or weak. It
does make the dates important. A lawyer reviewing a claim will usually
want to know when the shots started, how long they continued, when
symptoms began, when imaging found the tumor, and what doctors wrote in
the chart.

The science being discussed

The litigation has leaned heavily on medical literature about
progestogens and meningioma risk. One source often discussed is the 2024
BMJ French national case-control study on progestogens and intracranial
meningioma. Another is the 2025 JAMA Neurology study on depot
medroxyprogesterone acetate and meningioma risk in a large U.S. dataset.

Studies can support the legal fight, but they do not diagnose anyone.
They also do not decide whether a single person's tumor was caused by a
drug. That is why records matter so much in these cases.

A useful file usually includes injection records from an OB/GYN, clinic,
pharmacy, or health system; MRI or CT reports; pathology reports if
surgery happened; neurology or neurosurgery notes; and records showing
ongoing problems such as vision changes, headaches, hearing issues,
seizures, lost work, repeat imaging, radiation, or tumor recurrence.

The best first step is boring but important: get the paperwork. Portal
screenshots are better than nothing, but full medical records are
better. Injection dates matter. So do tumor location, date of diagnosis,
treatment history, and the state where the claim may need to be filed.

What to ask before assuming you qualify

If you are trying to figure out whether your family should have a
Depo-Provera meningioma claim reviewed, ask practical questions first.

Did the person receive Depo-Provera, Depo-SubQ Provera 104, or a generic
medroxyprogesterone acetate injection? Can the injections be documented?
Was there an imaging-confirmed cranial or spinal meningioma? Did use
happen before the December 2025 U.S. label change? Has any lawyer
checked the statute of limitations for the right state?

Those answers matter more than a headline about a possible settlement.
The public docket shows a large MDL, a July 2026 case count, an expert
hearing still on the calendar, and a settlement framework that may not
include every plaintiff.

Mass Tort America can review the basic timeline and help connect
families with lawyers handling Depo-Provera meningioma claims. A review
does not promise compensation, and no article can tell you whether your
claim will succeed.

This is attorney advertising and general information, not medical
advice. It does not create an attorney-client relationship. Talk with
your treating doctor about health questions. Talk with a lawyer promptly
about filing deadlines.

Sources checked: JPML MDL No. 3140 Transfer Order; JPML Pending MDL
Dockets by Actions Pending, July 1, 2026; Northern District of Florida
MDL No. 3140 Orders by Date; Pretrial Order No. 30A; FDA Depo-Provera CI
prescribing information revised December 2025; The BMJ 2024 progestogens
and intracranial meningioma study; JAMA Neurology 2025 depot
medroxyprogesterone acetate and meningioma study.